KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) EBIT Margin (2016 - 2026)

West Pharmaceutical Services has reported EBIT Margin over the past 18 years, most recently at 20.96% for Q1 2026.

  • Quarterly EBIT Margin rose 563.0% to 20.96% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 20.34% through Mar 2026, up 120.0% year-over-year, with the annual reading at 19.03% for FY2025, 67.0% down from the prior year.
  • EBIT Margin was 20.96% for Q1 2026 at West Pharmaceutical Services, up from 19.45% in the prior quarter.
  • Over five years, EBIT Margin peaked at 29.61% in Q2 2022 and troughed at 15.33% in Q1 2025.
  • The 5-year median for EBIT Margin is 21.31% (2024), against an average of 21.65%.
  • Biggest five-year swings in EBIT Margin: crashed -688bps in 2022 and later soared 563bps in 2026.
  • Tracing WST's EBIT Margin over 5 years: stood at 18.3% in 2022, then grew by 20bps to 21.98% in 2023, then dropped by -3bps to 21.31% in 2024, then dropped by -9bps to 19.45% in 2025, then grew by 8bps to 20.96% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 20.96%, 19.45%, and 20.83% for Q1 2026, Q4 2025, and Q3 2025 respectively.